If you struggle with treatment-resistant depression, Spravato™ may provide the help you need, delivering fast results so you can finally recover from ongoing depression. Ivan Cichowicz, MD, DABPN, is one of the leading experts in Spravato™ in south Florida. Dr. Cichowicz regularly lectures on Spravato™ and is a regular consultant to other providers in the area, wanting to incorporate the use of Spravato™ into their clinical practice. One of the biggest benefits of receiving treatment for your treatment-resistant depression at Mindful Behavioral Health PLLC is the fact that because we offer a variety of treatment modalities for treatment-resistant depression, we tailor treatment to you as opposed to trying to convince you that one treatment is best suited for every case. To learn more about this break-through medication and if you’re a good candidate, call the office in Boca Raton, Florida, or contact us online.
Spravato™ is the brand name for the prescription medication, esketamine, that’s produced by Janssen Pharmaceuticals, Inc. The United States Food and Drug Administration approved Spravato™ in March 2019 for use in adults with treatment-resistant depression in conjunction with an oral antidepressant.
You’re considered treatment-resistant when your depression doesn’t improve despite taking at least two antidepressants of adequate dose and duration. About 35% of adults taking antidepressants don’t respond to their medication.
Spravato™ is a nasal spray that’s absorbed through the nasal lining and directly into your bloodstream. It’s administered together with an oral antidepressant.
Spravato™ must be administered at a Spravato™ REMS certified health care center such as Mindful Behavioral Health.
Spravato™ is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if Spravato™ is safe or effective as an anesthetic medicine.
Spravato™ targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. The exact way that Spravato™ works is unknown.
Most patients who experience improvement from Spravato™ describe that their symptoms improve within the first two weeks of treatment. During the clinical trials, most patients improved within the first 24-48hrs, with some patients needing four weeks of treatment before they got better.
Click on this link to watch a Spravato™ informational video: https://www.spravato.com/treatment-with-SPRAVATO
Patients interested in Spravato™ treatment must schedule a consultation at Mindful Behavioral Health, with Ivan Cichowicz, MD DABPN, who is a Spravato™ specialist. During that consultation, Dr. Cichowicz will work on identifying if they're a good candidate for Spravato™ treatment. The requirements at present are to have a diagnosis of treatment-resistant depression, and to be taking an oral antidepressant; your insurance company may require other criteria.
Spravato™ is taken with a daily oral antidepressant. Patients will administer Spravato™ nasal spray themselves under the supervision of a healthcare professional at a certified Spravato™ treatment center. Following this, patients will stay at the certified Spravato™ treatment center for 2hrs so they can be monitored for side effects. You’ll need to plan for rides to and from the certified Spravato™ treatment center as you should not drive or operate machinery until the day after a treatment session, following a restful sleep. You may want to bring a book, a relaxing playlist, or another form of entertainment for the session because of the two hour monitoring period after treatment. Mindful Behavioral Health will do its best to provide you with a Tv or tablet with either Netflix or Hulu during treatment. Additionally, Mindful Behavioral Health will guarantee that all patients receiving Spravato™ will be in a comfortable and private room, additionally family will be able to be present during the full time of treatment if they so desire.
Spravato™ is taken twice a week for the first four weeks; then, the Spravato™ treatment dosing is adjusted to once a week for another four weeks. After this treatment is provided at either weekly or biweekly intervals, some patients may be able to stop Spravato™ after the first eight weeks of treatment, but during the clinical trials, patients who stayed on Spravato™ longer tended to do better than those who stopped the medication.
The most common side effects reported during the clinical trials for Spravato™ include dissociation (41%), dizziness (29%), nausea (28%), sedation (23%), reduced sense of touch and sensation (18%), anxiety (13%), lack of energy (11%), temporary increased blood pressure (10%), vomiting (9%) and the sensation of being drunk (5%). It is important to remember that these are not the only possible side effects, just the most commonly reported. Each patient's experience may be different. Because of the possibility of these side effects, patients must stay at Mindful Behavioral Health for two hours following Spravato™ treatment. For most patients, most if not all side effects will have subsided after two hours.
Because of the risk of side effects, we recommend that patients not eat or drink for the two hours before receiving treatment with Spravato™.
Additionally, during the Spravato™ clinical trials, less than 5% of patients discontinued treatment due to side effects.
The safety and benefits of Spravato™ were studied in a clinical program involving short- and long-term trials across more than 1,700 adult patients with treatment-resistant depression that compared Spravato™ plus an oral antidepressant to a placebo nasal spray plus an oral antidepressant. These studies evaluated the efficacy and safety of Spravato™ in both short-term and long-term studies for up to one year.
To learn if you’re a good candidate for Spravato™, call Mindful Behavioral Health or contact us online.